Contribution of tRNA fragments in the ETiopathogenesis of Huntington's Disease (...
Contribution of tRNA fragments in the ETiopathogenesis of Huntington's Disease (tR-GET HD)
Many pathogenic mechanisms are involved in Huntington’s disease (HD), the most prevalent monogenic neurological disease in Europe, with no current cure. The host team reported a dysregulation of tRNA-fragments (tRFs) in HD brains;...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
SAF2017-88452-R
ANALISIS DE ARNS CON REPETICIONES CAG COMO FACTORES PATOGENI...
Cerrado
PID2020-116474RB-I00
DESCIFRANDO EL PAPEL DE LA METILACION M6A DEL ARN COMO UN NU...
169K€
Cerrado
TransSplicHD
Single Cell Transcriptomics and Spliceosome analysis to unco...
180K€
Cerrado
PID2020-113953RB-I00
FRAGMENTOS DE LOS TRNAS COMO MEDIADORES DE LOS PROCESOS NEUR...
203K€
Cerrado
SWITCH-HD
Switching the disease off Effects of spatial and temporal i...
999K€
Cerrado
HUNTINFISH
Generation of new zebrafish models for the study of the path...
183K€
Cerrado
Información proyecto tR-GET HD
Duración del proyecto: 26 meses
Fecha Inicio: 2022-08-11
Fecha Fin: 2024-10-14
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Many pathogenic mechanisms are involved in Huntington’s disease (HD), the most prevalent monogenic neurological disease in Europe, with no current cure. The host team reported a dysregulation of tRNA-fragments (tRFs) in HD brains; other studies showed higher stress granules' (SG) density in HD, and that tRFs promote SG assembly. Thus, my hypothesis is that HD-related tRFs contribute to the accumulation of SG, initiating mutant huntingtin (mtHTT) aggregation and leading to disease pathogenesis. I propose to explore the interaction between mtHTT aggregates, and tRFs and SG, as new potential therapeutic targets. Specifically, I aim to study the 1) cell-type specificity of tRFs formation and their correlation with HD progression; 2) molecular mechanisms by which tRFs may induce HD pathology; and 3) potential of tRFs modulators to treat mtHTT-related neurotoxicity.
This project’s success relies on the perfect synergy of the host team’s expertise in tRFs biology and HD and my own experience in RNA and proteotoxicity in neurodegenerative diseases, thoroughly addressing the hypothesis via complementary human, cellular and mice HD models and a plural array of bioinformatic, molecular biology and genomic approaches. The outcomes will help define the role of tRFs and SG in mtHTT aggregation, and may be used as preclinical proof-of-concept for novel HD therapies, reflecting the project’s translational potential.
I will benefit from scientific exchanges with expert neuroscientists in the host institution, particularly my supervisor, whose skills in functional genomics fully match my expertise in RNA and protein pathological mechanisms. My translational technical knowledge and network of collaborators will be useful to the host group to build new cooperative projects. Thus, the MSCA fellowships will allow me to develop unique technical and transferable skills, helping me progress and establish myself as a leader in neurodegenerative research within a European research institute.